Side effects: Most patients have no significant side effects
iu ny c th gip bo v da tt hn trc tia UV t nh nng mt tri
GLP-1 weight loss medications have become a cornerstone of medically supervised weight loss , helping patients reduce appetite, improve portion control, and support sustainable fat loss
Bettencourt, N., Wilson, C
Long-term results and expectations beyond year one Research following semaglutide users beyond one year shows maintained weight loss in those who continue medication, with average losses stabilizing around 15 to 17 percent of starting weight
In December 2025, federal courts consolidated NAION lawsuits into an MDL proceeding in the Eastern District of Pennsylvania